For the treatment of Achalasia, LHM has been the only surgical therapy. Recently, an endoscopic approach for this therapy has been developed (peroral endoscopic Myotomy POEM). Studies show promising short and mid term results for POEM. At present, POEM is considered a promising new technique with the potential to become a standard achalasia treatment. For this to happen, long-term comparative data with LHM is required. Therefore,the intention for this study is to investigate the short and long-term efficacy of POEM for the treatment of achalasia as it was performed in international centers and compare outcomes with database assessment of LHM.
Achalasia is a neurodegenerative esophageal motility disorder characterized by incomplete lower esophageal sphincter (LES) relaxation, increased LES tone, and aperistalsis of the esophagus. The standard surgical treatment for achalasia is laparoscopic Heller Myotomy (LHM). A recent meta-analysis of 105 studies reporting on 7855 patients demonstrated that laparoscopic Heller myotomy is the most effective and long-lasting therapy for achalasia. Superior to Endoscopic balloon dilatation or Botulinumtoxin injection LHM has a one year therapeutic efficacy in approximately 90% of patients. Recently an endoscopic technique emulating the principles of LHM was developed. This technique of a purely endoscopic myotomy has been demonstrated by Pasricha et al. in animal experiments and Inoue et al. reported the first clinical study. Other pilot studies and a larger international multi-center trial have replicated promising results for POEM. Uncontrolled studies show promising short and mid term results for POEM. At present, POEM is considered a promising new technique with the potential to become a standard achalasia treatment. For this to happen, however, comparative data with LHM is required. Our study group intends to investigate the short and long-term efficacy of POEM for the treatment of achalasia as it was performed in international centers and compare outcomes with database assessment of LHM.
Study Type
OBSERVATIONAL
Enrollment
47
Aarhus University Hospital
Aarhus, Denmark
University Hospital Eppendorf
Hamburg, Germany
University Medical Center
Mainz, Germany
Academic Medical Center
Amsterdam, Netherlands
University Hospital
Zurich, Switzerland
treatment success
treatment success is defined as an Eckardt Score \</=3
Time frame: 1 year after treatment
procedure related adverse events
retrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure
Time frame: 3 months after treatment
lower esophageal sphincter pressure (LESP)
retrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure
Time frame: 3 months after treatment
symptomatic reflux and use of antacid medication
retrospective data for this timepoint can be used of the interval 2-8 months after the initial procedure
Time frame: 3 months after treatment
procedure related adverse events
retrospective data for this timepoint can be used of the interval 9-15 months after the initial procedure
Time frame: 12 months after treatment
lower esophageal sphincter pressure (LESP)
retrospective data for this timepoint can be used of the interval 9-15 months after the initial procedure
Time frame: 12 months after treatment
symptomatic reflux and use of antacid medication
retrospective data for this timepoint can be used of the interval 9-15 months after the initial procedure
Time frame: 12 months after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.